SI-B001 + FOLFIRI

SI-B001 + FOLFIRI is an investigational **combination therapy** under clinical development for advanced or metastatic solid tumors, primarily metastatic colorectal cancer. SI-B001 is a novel agent whose precise molecular characterization is not fully disclosed in public sources yet, but is known to be combined with the FOLFIRI regimen in clinical trials. FOLFIRI is a well-established chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan, each of which disrupts cancer cell growth through complementary mechanisms. This regimen is administered in cycles and works by: - enhancing 5-FU's binding to its target protein (leucovorin), - blocking DNA synthesis and repair (5-FU), - inhibiting topoisomerase I to prevent cancer cell division (irinotecan)[1][3][7]. The addition of SI-B001 aims to further improve efficacy, though public documentation of SI-B001’s exact mechanism and target is limited. The combination is being studied for efficacy, safety, and tolerability in patients who have failed standard treatments.